A Study of ICP-192 in Patients With Advanced Solid Tumors

Summary

This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.

Timeline

Start

2021-02-01

Primary completion

2023-11-30

Completion

2024-04-15

Drugs

Indications